Last Updated 4 December 2015
The term dyslipidemia refers to abnormalities in the composition, concentration, or size of lipoproteins in the circulation. Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease, but has historically been underdiagnosed in patients because of its asymptomatic nature and the lack of screening programs across markets. Treatment of dyslipidemia and therapeutic research have chiefly centered on reducing the levels of atherogenic lipids; agents that target low-density lipoprotein (LDL) cholesterol have enjoyed particular commercial success owing to their demonstrated ability to reduce CV risk. However, the focus of R&D is shifting away from simply improving the concentration of circulating lipids and more toward improving the composition and functionality of lipoproteins and their components. Importantly, physicians and regulatory authorities are no longer satisfied with just improvement in lipid profile and are seeking evidence of CV outcomes benefits. During the 2014-2024 forecast period, the dyslipidemia market is expected to have two distinct phases. Over the first half of the study period, the continuing genericization of the dominant statin class and reduced use of many older nonstatin therapies will eventually see a contraction of the market. However, the second half will see marked growth in the market owing to the emergence of keenly awaited novel therapies. including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.